Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR
While first line targeted therapies are the current standard of care treatment for non-small cell lung cancer (NSCLC) with actionable mutations, the cancer cells inevitably acquire resistance to these agents over time. Immune check-point inhibitors (ICIs) have improved the outcomes of metastatic NSC...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Frontiers Media S.A.
2021
|
| Subjects: | |
| Online Access: | https://doaj.org/article/9e3739d66fd3419fb78b4fe693d766c2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|